Eurofins Spinnovation Analytical

ChromaCon AG is a private Swiss Life Science tool company, developing and commercializing proprietary chromatographic process technology.

Our vision is to transform bioprocessing to continuous and our mission is to provide best-in-class tools consisting of equipment, reagents and discovery technologies to help our customers to create, develop and manufacture next-generation chemical and biological medicines.

We facilitate the conversion from batch to more efficient continuous processes by offering equipment, processes and software designed to ease the conversion from batch to continuous chromatography.

We are unique in providing laboratory-scale FPLC and HPLC equipment for the purification of proteins and small molecules. The systems have multiple process capabilities allowing our customers to choose the best purification process for any given purification challenge:

• conventional batch and two-step connected batch for efficient high throughput batch purification
• periodic countercurrent processes (PCC) for continuous capture and polish purification
• novel processes for discovery applications facilitating the isolation of minor components from complex mixtures

Continuous manufacturing offers 30-50% reduction in CAPEX and OPEX compared to conventional batch manufacturing and is emerging to replace batch manufacturing. ChromaCon is unique in having a full range of process and process control patents and offering together with its scale-up partner a one-stop solution from laboratory to GMP process scale.

Transforming proteins into pioneering drugs

ProJect Pharmaceutics, based in Martinsried/Munich, Germany, transforms proteins, peptides and delicate small molecules into pioneering drugs. ProJect Pharmaceutics adds value to client´s bio-pharmaceutical products by applying an innovative concept of development called Advaceutics. Based on the Advaceutics concept, ProJect Pharmaceutics designs optimized formulations and delivery systems for biologics that are stable, convenient and safe. Tailored to these optimized systems the company develops cost-effective manufacturing processes and transfers those from its own pilot labs to large-scale manufacturing. ProJect Pharmaceutics makes sure that investigational products, biosimilars as well as “bio-betters” are developed effectively and will run smoothly in clinical and commercial scale GMP manufacturing.

We offer:
• predictive formulation analytics
• formulation development including in-depth protein analytics
• lyophilization process development and optimization
• lyophilization in dual chamber prefilled syringe
• development of liposomal formulations, producible by simple stirring
• manufacturing of preclinical study material
• technology-transfer including scale-up to GMP-manufacturer

We deliver:
• optimized formulations for biopharmaceuticals
• tailored manufacturing processes and transfer to GMP manufacturing
• development reports ready for submission to the authorities for registration

Our injectable and solid form products are manufactured in the Madrid metropolitan area in Spain. These CMO (or Contract Manufacturing Organizations) facilities are owned by ROVI Pharma Industrial Services®, a specialized Spanish pharmaceutical company, fully dedicated to research, development, manufacture and marketing of small molecules and biologicals.

In 2012, ROVI’s injectable plants received FDA approval.

From project development to product release, as well as pilot and industrial batches, ROVI® brings all of these services into a single company, allowing our clients to save considerable time and money as a result.

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) in H1 2021. Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in H1 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in H1 2021. Addex’s GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex is listed on the SIX Swiss Exchange and NASDAQ Capital Market, and trades under the ticker symbol "ADXN".

Blood Assay Solutions is specialized in whole blood assays using fresh blood.
We develop customized assays based on the use of fresh whole blood to suit your needs for discovery and preclinical programs.

Whether you are:
• A biotech or a pharmaceutical company developing biologics or small molecules
• A manufacturer of research products (reagents, cell culture plasticware)
• A company producing cosmetics
• A company developing food supplements

There are blood assays to support and to speed up the decision-making process.